From Medscape Oncology

Coverage from the

American Society of Clinical Oncology (ASCO) 2018 Annual Meeting

June 01 - 05, 2018; Chicago, Illinois

June 01 - 05, 2018 Chicago, Illinois
  • ASCO 2018 'End of an Era' for Chemo in Non-Small Cell Lung Cancer The fear of unsupportable adverse effects from chemotherapy can be laid to rest for most patients with non-small cell lung cancer, say experts at the world's largest cancer meeting.
  • ASCO 2018 Chemo Not Needed for Most Early Breast Cancer: TAILORx Practice-changing results from the TAILORx trial have confirmed that about 70% of patients with hormone-positive early breast cancer will not benefit from adjuvant chemotherapy.
  • ASCO 2018 In Advanced Kidney Cancer, Surgery No Longer Sole Standard of Care The management of patients with metastatic renal cell carcinoma has changed with the advent of targeted therapy. Now a major clinical trial indicates that those drugs alone are sufficient for many of these patients.

Meeting Highlights At A Glance

  • Top News From ASCO 2018: Slideshow Top News From ASCO 2018: Slideshow Highlights include practice-changing data in advanced non-small cell lung cancer, early breast cancer, and kidney cancer, plus welcome news of $10 million in new funding for research.

Conference News

Popular News from ASCO 2017

Medscape Oncology© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Medscape Oncology Perspectives


Previous Coverage